Drug Profile
Insulin polysialic - Xenetic Biosciences
Alternative Names: Polysialic insulin - Xenetic Biosciences; Polysialylated insulin - Xenetic/Synbio; Recombinant human insulin - Xenetic Biosciences; SuliXen; SYN20090110RU; SYN20090510RULatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Lipoxen Technologies
- Developer SynBio; Xenetic Biosciences
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones; Small interfering RNA
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus